<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Opus Genetics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/opus-genetics-inc</link>
<description>Latest news and press releases for Opus Genetics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 13 May 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/opus-genetics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683584ce78dffbe2df0fd418.webp</url>
<title>Opus Genetics, Inc.</title>
<link>https://6ix.com/company/opus-genetics-inc</link>
</image>
<item>
<title>Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-to-present-at-the-rbc-capital-markets-2026-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-to-present-at-the-rbc-capital-markets-2026-global-healthcare-conference</guid>
<pubDate>Wed, 13 May 2026 11:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 11:00 a.m. ET. A link to the live and archived webcast may be accessed o</description>
</item>
<item>
<title>Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-completes-enrollment-in-cohort-1-of-phase-12-opgx-best1-gene-therapy-study</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-completes-enrollment-in-cohort-1-of-phase-12-opgx-best1-gene-therapy-study</guid>
<pubDate>Thu, 07 May 2026 11:00:00 GMT</pubDate>
<description>Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide Presentation Available on Opus Website Three-Month Topline Results from Cohort 1 Expected in September 2026 RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene</description>
</item>
<item>
<title>Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program</guid>
<pubDate>Mon, 04 May 2026 20:30:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration’s (FDA) Rare Disease Evidence Principles (RDEP) program. OPGx-LCA5</description>
</item>
<item>
<title>Opus Genetics to Participate in Leading Medical Conferences in May 2026</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-to-participate-in-leading-medical-conferences-in-may-2026</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-to-participate-in-leading-medical-conferences-in-may-2026</guid>
<pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences. “We look forward to sharing progress across our programs at ARVO and other leading</description>
</item>
<item>
<title>Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting</guid>
<pubDate>Fri, 10 Apr 2026 10:59:00 GMT</pubDate>
<description>Oral presentations feature phentolamine ophthalmic solution 0.75%RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in</description>
</item>
<item>
<title>Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland-capital</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland-capital</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>- Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment -- Strategic</description>
</item>
<item>
<title>Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026</guid>
<pubDate>Tue, 24 Mar 2026 11:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026 in the Biotech category. This year’s list shines a spotlight on businesses that are shaping</description>
</item>
<item>
<title>Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-financial-results-for-full-year-2025-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-financial-results-for-full-year-2025-and-provides-corporate-update</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected</description>
</item>
<item>
<title>Opus Genetics to Present at Upcoming Investor Conferences in March 2026</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-to-present-at-upcoming-investor-conferences-in-march-2026</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-to-present-at-upcoming-investor-conferences-in-march-2026</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the following investor conferences. Leerink Global Healthcare Conference Date: Tuesday, March 10, 2026Time: 3:00 p.m. ETLocation: Miami, FL Citizens Life Sc</description>
</item>
<item>
<title>Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-initial-clinical-data-from-phase-12-opgx-best1-gene-therapy-study-at-the-macula-society-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-initial-clinical-data-from-phase-12-opgx-best1-gene-therapy-study-at-the-macula-society-annual-meeting</guid>
<pubDate>Fri, 27 Feb 2026 15:10:00 GMT</pubDate>
<description>Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and structural improvement observed at one month and three months12-letter BCVA gain and 23% CST reduction observed in the treated eye at three monthsFull cohort data expected in mid-year 2026 RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics”</description>
</item>
<item>
<title>Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-fda-acceptance-of-supplemental-new-drug-application-for-phentolamine-ophthalmic-solution-075percent-for-the-treatment-of-presbyopia</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-fda-acceptance-of-supplemental-new-drug-application-for-phentolamine-ophthalmic-solution-075percent-for-the-treatment-of-presbyopia</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>FDA PDUFA Goal Date Set for October 17, 2026 RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus</description>
</item>
<item>
<title>Opus Genetics Announces $25 Million Private Placement</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-25-million-123000981</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-25-million-123000981</guid>
<pubDate>Fri, 13 Feb 2026 12:30:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has entered into a securities purchase agreement for a private placement (the “private placement”) of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock at a pr</description>
</item>
<item>
<title>Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-participate-upcoming-medical-130000589</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-participate-upcoming-medical-130000589</guid>
<pubDate>Mon, 02 Feb 2026 13:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences. Collaborative Community on Ophthalmic Innovation (CCOI) Topic: Opus Genetics</description>
</item>
<item>
<title>Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-launches-gene-therapy-120000538</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-launches-gene-therapy-120000538</guid>
<pubDate>Tue, 27 Jan 2026 12:00:00 GMT</pubDate>
<description>The trial is funded through Abu Dhabi’s Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa affects an estimated 60,000 patients worldwide RESEARCH TRIANGLE PARK, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRD</description>
</item>
<item>
<title>Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference</title>
<link>https://6ix.com/company/opus-genetics-inc/news/senti-bio-to-participate-in-panel-presentation-at-biotech-showcase-alongside-the-jp-morgan-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/senti-bio-to-participate-in-panel-presentation-at-biotech-showcase-alongside-the-jp-morgan-annual-healthcare-conference</guid>
<pubDate>Fri, 09 Jan 2026 13:55:00 GMT</pubDate>
<description>Live panel presentation on Tuesday, January 13th at 8:00 AM PTSOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Dr. Timothy Lu, Co-Founder and CEO, will participate as a panelist alongside Jonah Comstock, Editor in Chief, pharmaphorum; Jay Hartenbach, President & COO, Diakonos</description>
</item>
<item>
<title>Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-highlights-2025-progress-120000654</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-highlights-2025-progress-120000654</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>- Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 -- Supplemental New Drug Application (sNDA) submitted for partnered presbyopia treatment - - Corporate presentation at J.P. Morgan Healthcare Conference on Thursday, January 15, at 8:15 a.m. PT - RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company,” “Opus,” or “Op</description>
</item>
<item>
<title>Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-reports-inducement-grant-210100464</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-reports-inducement-grant-210100464</guid>
<pubDate>Tue, 16 Dec 2025 21:01:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Compensation Committee of its Board of Directors approved an equity award under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to one non-e</description>
</item>
<item>
<title>Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-present-j-p-120000877</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-present-j-p-120000877</guid>
<pubDate>Thu, 11 Dec 2025 12:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, announced today that George Magrath, M.D., Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 8:15 a.m. PT. A link to the live and archived webcas</description>
</item>
<item>
<title>Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-positive-recommendation-120000903</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-announces-positive-recommendation-120000903</guid>
<pubDate>Tue, 09 Dec 2025 12:00:00 GMT</pubDate>
<description>Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trialRESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Independent Data Monitoring Committee (IDMC) issued a positive recommendation to continue as planned in the Comp</description>
</item>
<item>
<title>Opus Genetics to Participate in Upcoming Investment Conferences</title>
<link>https://6ix.com/company/opus-genetics-inc/news/opus-genetics-participate-upcoming-investment-130000840</link>
<guid isPermaLink="true">https://6ix.com/company/opus-genetics-inc/news/opus-genetics-participate-upcoming-investment-130000840</guid>
<pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in the following investor conferences. BTIG 5th Annual Ophthalmology Day (Virtual): Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will</description>
</item>
</channel>
</rss>